Vervain

Vervain (Verbena officinalis L.): A Comprehensive Reference

1. Identity and Botanical Description

Scientific Classification and Nomenclature

Verbena officinalis L. (family Verbenaceae) is known as the herb of grace, pigeon's grass, and vervain. The genus name Verbena originates from the Latin term verbēna, meaning "sacred bough" or "leafy branch," referring to twigs or foliage used in ancient Roman religious ceremonies. The specific epithet officinalis stems from officina, denoting a workshop or apothecary, indicating the plant's longstanding role as a medicinal herb stocked in pharmacies for therapeutic preparations.

The scientific name is Verbena officinalis (L.) Wettst. Common names include: Enchanter's plant, Erba croce, Erba dei tagli, Herb of grace, Herb of the cross, Juno's tears, Pigeon's grass, Pigeonweed, Prostrate verbena, Verbena, Vervain, and Yerba de Santa Ana. Common names in many Central and Eastern European languages often associate it with iron, including the Dutch IJzerhard ("iron-hard"), Danish Læge-Jernurt ("medical ironwort"), German Echtes Eisenkraut ("true ironherb"), Slovak Železník lekársky ("medical ironherb"), and Hungarian vasfű ("iron grass").

It is important to distinguish common vervain (Verbena officinalis) from lemon verbena (Aloysia citrodora, syn. Lippia citriodora), which belongs to the same family but is a distinct species with different chemistry and a characteristic lemon scent. Verbena officinalis is traditionally used for digestive and nervous comfort, while lemon verbena (Aloysia citrodora, also called verveine citronnelle) is found in most commercial herbal teas due to its characteristic citrus scent.

Morphology and Distribution

V. officinalis is a perennial erect small herb that grows up to 25–100 cm in height with lobed and serrated leaves. Pink or purple is the color of flowers. It is a perennial herbaceous plant that prefers sunny locations with dry soils and can be found as a ruderal species near roads, on stone rubble, in fields, and wastelands.

The natural habitats of V. officinalis are widespread throughout the world — in Europe, the Americas, North and Central Africa, Asia, and Australia. This species grows mainly in temperate climate zones. In Europe, it is common in the Mediterranean region.

Plant Parts Used and Common Preparations

Verbenae herba, a raw material consisting of the aerial parts, is included in both the Chinese Pharmacopoeia and the European Pharmacopoeia. The leaf and flower are used in herbal medicine. Common preparation forms include dried herb infusions (teas/herbal teas), hydroalcoholic tinctures, decoctions, and topical lotions. Externally, verbena herb infusion serves as a gargle for tonsillitis and stomatitis, and as a lotion for skin conditions.

Pharmacopoeial Status

Monographs on Verbenae herba have been included in the European Pharmacopoeia since 2008, and in the Chinese Pharmacopoeia since 1995. Verbena officinalis is included in the HMPC community herbal monograph of the EMA. Regarding standardization, the raw material is standardised based on its phenylethanoid content, specifically the tyrosol derivative acteoside (verbascoside), which must comprise a minimum of 2.5% of dry weight, expressed as ferulic acid. The essential oil content should be at least 3.0 mL/kg in the whole drug and 2.0 mL/kg in the fragmented drug (dry weight).

2. Traditional and Historical Use

Ancient Mediterranean Cultures

Vervain was called "tears of Isis" in Ancient Egypt, and later "Juno's tears." In Ancient Greece, it was dedicated to Eos Erigineia. In Roman practices, it was known as the "altar plant" and used to purify temples and sacred spaces, often burned as incense or scattered during rituals. Celtic druids also regarded it as a sacred herb associated with the goddess Venus and druidic rites. Celtic druids revered it for its protective qualities, incorporating it into ceremonies for warding off evil and enhancing spiritual connections.

Medieval Europe

In early medieval Europe, some accounts stated that common vervain was used to staunch Jesus' wounds after his removal from the cross; hence names like "Holy Herb" or (in Wales) "Devil's bane." Because of the association with the Passion of Christ, it came to be used in ointments to drive out and repel "demonic" illness. Ethnopharmacological records of ancient uses of this plant are well documented and confirm that it was considered a "sacred herb" in European folk medicine.

Folk Medicine Applications Across Cultures

This widely distributed species is used in folk medicine of various countries and in traditional Chinese medicine for the treatment of many ailments: rheumatism, anxiety, depression, insomnia, bronchitis, dysmenorrhea, amenorrhea, throat swelling, abscesses, edema, jaundice, malaria, and liver and gallbladder diseases.

In the European tradition, vervain held a prominent place in domestic medicine. Verbena has traditionally been used in folk medicine to support nervous system health and aid conditions such as stress, anxiety, depression, and insomnia. Moreover, it has been utilised for headache relief, premenstrual tension, and the treatment of cramps, jaundice, and asthma. The common vervain was boiled in wine and drunk to soothe pains and gout of the feet, or crushed to be rubbed on the affected body parts.

Vervain has been used for many conditions, including stimulation of lactation and treatment of dysmenorrhea, jaundice, gout, kidney stones, and headache.

In traditional Chinese medicine, vervain has a long history of application with well-documented records. V. officinalis is a kind of traditional Chinese medicine, which has a long history of application and shows good effects on neuroprotection. In 1985, it was the first time that V. officinalis L. was reported to have antitussive effect, which was associated with the component verbenalin, as documented by Gui Chenghui in China.

3. Key Constituents and Active Compounds

Overview of Chemical Profile

Vervain is a rich source of iridoids, phenylpropanoid glycosides, phenolic acids, flavonoids, terpenoids, and essential oil. A total of eight main phenolic compounds and 17 amino acids have been determined in V. officinalis dry extracts.

Iridoid Glycosides

The most characteristic chemical constituents of vervain are the iridoid glycosides verbenalin and hastatoside. Also prominent is the caffeic acid glycoside verbascoside, which is found in a number of other medicinal plants. Chromatographic purification of the methanol extract yields two iridoid glucosides (verbenalin and hastatoside), a phenylpropanoid glycoside (verbascoside), and β-sitosterol-D-glucoside. Aucubin has also been found as one of the active constituents.

Hastatoside and verbenalin have sleep-promoting (soporific) properties. Flavonoids and iridoid glycosides are reported to be important active constituents most contributing to the pharmacological efficacy of V. officinalis.

Phenylpropanoid Glycosides

Verbascoside (VB), an active phenylethanoid glycoside, possesses anti-inflammatory, antioxidative, and anti-apoptotic effects. Verbascoside can be isolated from medicinal plants commonly used in folk medicine, such as Verbascum thapsus (common mullein), Verbena officinalis (common vervain), Plantago lanceolata, and Olea europaea (olive). The anti-inflammatory activity of verbascoside has been confirmed by an in vitro test performed on cell cultures of primary human keratinocytes, in which verbascoside was able to significantly reduce, in a dose-dependent manner, the release of pro-inflammatory chemokines.

Flavonoids

Among notable compounds in V. officinalis, flavonoids include apigenin, luteolin, 5,7,4′-trihydroxy-8-methoxyflavone, scutellarein and its glucoside derivatives (scutellarein 7-glucoside, scutellarein-7-diglucuronide, and scutellarein-7-glucuronide). Additionally, the plant contains pedalitin, pedalitin-6-galactoside, quercetin, kaempferol, isorhamnetin, diosmetin, and rutin. Flavonoids such as luteolin 7-diglucuronide have been isolated in vervain, as have ursolic acid, sterols, and several related triterpenes.

Terpenoids and Sterols

Chemical investigations of petroleum ether and chloroform extracts led to the isolation of β-sitosterol, ursolic acid, oleanolic acid, 3-epiursolic acid, 3-epioleanolic acid, and minor triterpenoids of derivatives of ursolic acid and oleanolic acids. Among monoterpenoids, the key compounds include citral, limonene, eucalyptol, menthol, α-pinene, β-pinene, sabinene, and β-phellandrene. The most abundant sesquiterpenoids are caryophyllene oxide, α-curcumin, β-caryophyllene, hexahydrofarnesylacetone, and spathulenol.

The essential oil composition of V. officinalis varies greatly depending on the geographical location and the specific plant part used in distillation.

Relevant Mechanisms of Action

Antiphlogistic activities of β-sitosterol, phenylpropanoids like verbascoside, iridoids such as verbenalin and hastatoside, ursolic acid, and other triterpenoids have been demonstrated. For the nervous system, research using preclinical models has pointed to involvement of GABAergic and related pathways. In a thiopental-induced sleeping test, a crude extract of V. officinalis (50–300 mg/kg) decreased onset time of sleep while increasing the duration of sleep, indicating that Verbena officinalis possesses anticonvulsant, anxiolytic, and sedative activities, which provides scientific background for its medicinal application in various neurological ailments such as epilepsy, anxiety, and insomnia.

For the anti-Alzheimer's mechanisms of verbascoside specifically, proteomic analysis demonstrated that the neuroprotection of verbascoside correlated closely to its anti-inflammatory effect; it significantly blocked microglia and astrocyte activation in the brains of APP/PS1 mice, suppressed the generation of IL-1β and IL-6, and boosted that of IL-4, IL-10 and TGF-β. Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) identified the main chemical components in V. officinalis as iridoid glycosides, phenylethanoid glycosides, and flavonoids, and molecular docking showed these compounds had good anti-AD activity.

4. Scientific Evidence by Area of Use

4.1 Neurological and Psychiatric Effects (Anxiety, Depression, Sedation)

Preclinical (animal/in vitro) evidence: To evaluate the neurotropic effects of verbena extracts, behavioural pharmacology tests were used including the Open Field Test, Elevated Plus Maze, Black-and-White Box Test, and Tail Suspension Test. The dry aqueous–ethanolic extract (70% ethanol) demonstrated strong anxiolytic and antidepressant effects, while dry modified extracts with valine and arginine consistently exhibited pronounced sedative activity across all studies.

A preclinical study concluded that Verbena officinalis L. aqueous extract at a dose of 200 mg/kg could have an antidepressant effect in adult rats. This study evaluated the antidepressant effect in female rats using the Forced-Swimming Test (FST), Light-Dark Box (LDB) test, and Open Field Test (OFT).

Clinical evidence: Human clinical trials remain scarce. Many studies rely on animal or cell-culture data, making direct translation to people uncertain. No human studies have documented the use of this herb for any condition pertaining to neuropsychiatric endpoints specifically, as of assessments available in the medical literature.

4.2 Sleep Promotion

Preclinical evidence: An in vivo study investigated the sleep-promoting effects of compounds found in vervain. The three major iridoids — hastatoside, verbenalin, and verbascoside — were investigated. Researchers used electroencephalographic (EEG) scans to measure the brain activity of rats after oral administration. Hastatoside (0.64 mmol/kg of body weight) and verbenalin (1.28 mmol/kg of body weight) showed a significant improvement in non-rapid eye movement sleep during a 9-hour period by 81% and 42%, respectively.

This constitutes preclinical (rodent) evidence only. No controlled human clinical trials specifically examining V. officinalis for sleep have been identified.

4.3 Anti-inflammatory and Analgesic Effects

Preclinical evidence: Various different extracts of Verbena officinalis (petrol ether, chloroform, methanol extract, flavonoid-enriched extract, and CO2 extract) inhibited carrageenan-induced rat paw oedema. The strongest inhibition was achieved with the CO2 extract. The methanolic extract and the flavonoid-rich extract reduced inflammation by 38% and 34%, respectively. The extract obtained using carbon dioxide in a supercritical state exhibited the highest activity, reducing inflammation by 61%.

Anti-inflammatory, analgesic, and antioxidant activities have been reported for this plant. Analgesic and anti-inflammatory activity justify its use to relieve menstrual symptoms.

Evidence strength: These anti-inflammatory findings are at the level of animal models and in vitro assays. No controlled human trials specifically examining V. officinalis mono-preparations for pain or inflammation in human subjects have been identified in the sources reviewed.

4.4 Oral Health / Gingivitis

Clinical evidence — the strongest available for V. officinalis as a mono-preparation: A double-blind, randomized, controlled, multicenter clinical trial evaluated the clinical efficacy of Verbena officinalis decoction for patients with chronic generalized gingivitis. Patients in both groups were instructed to brush and floss, while additionally patients in the test group rinsed their mouths with a V. officinalis L. decoction. The primary clinical outcome was the Gingival Index (GI), measured at baseline (day 0), day 14, and day 28. Two hundred and sixty patients participated (control group = 130, test group = 130). The tested V. officinalis decoction demonstrated efficacy in reducing tested indices and thus has a promising ameliorative effect for treating patients with chronic generalized gingivitis. V. officinalis decoction showed good clinical results with no adverse effects.

Evidence strength: This RCT (n = 260) is the most robust human clinical trial identified for V. officinalis as a single-herb preparation. Its findings are promising but limited to a specific oral health application, and independent replication is needed.

4.5 Respiratory Conditions / Sinusitis (Combination Product)

A product popular in Germany containing vervain along with gentian root, primrose, sorrel, and elderflower (known commercially as Sinupret) is used to treat sinusitis alongside traditional antibiotics. The combination of herbs is supposed to increase mucus drainage. Verbena is possibly safe when taken by mouth in small amounts as part of this combination product containing gentian root, elderflower, sorrel, and cowslip flower (SinuComp, Sinupret). The clinical evidence in these studies pertains to the multi-herb combination, not to vervain in isolation, and the contribution of vervain specifically cannot be disaggregated from these trials.

4.6 Neuroprotection and Alzheimer's Disease

Preclinical and in vitro evidence: As extracellular accumulation of Aβ peptide is an important cytotoxic factor involved in Alzheimer's disease (AD), researchers explored the neuroprotective effect of V. officinalis against Aβ. Treatment with V. officinalis attenuated Aβ-triggered DEVD- and VDVAD-cleavage activities in a dose-dependent manner. Neurons treated in vitro with aqueous extract showed both reduced destruction of neurites and reduced neuronal apoptosis. The plant aqueous extract may play a role by inhibiting the activation of caspase-2 and caspase-3 by nerve cells.

These studies conclude that vervain shows significant novel neuroprotective effects in vitro and are described as a lead for its potential to be a neuroprotective agent against neuronal loss in Alzheimer's disease. Further research is needed to fully understand its efficacy using clinical trial methods in human subjects.

Evidence strength: All neuroprotection evidence for V. officinalis itself is preclinical (cell culture and animal models). No human clinical trials for Alzheimer's disease or general neuroprotection have been reported.

4.7 Antimicrobial Effects

V. officinalis showed good in vitro antibacterial activity against Staphylococcus aureus, Escherichia coli, and Salmonella typhi. Verbascoside, a key constituent of vervain, exhibits a wide range of biological activities including antioxidant, anti-inflammatory, anti-diabetic, cardiovascular, and hepatoprotective properties.

Evidence strength: Antimicrobial effects have been demonstrated in vitro only. No controlled human trials have assessed V. officinalis as an antimicrobial agent.

4.8 Anticonvulsant Activity

Results from preclinical studies indicate that Verbena officinalis possesses anticonvulsant, anxiolytic, and sedative activities, which provides scientific background for its medicinal application in various neurological ailments such as epilepsy, anxiety, and insomnia. These studies are animal-based. No human clinical trials for anticonvulsant use have been identified.

4.9 Antitussive Effects

The total extract of V. officinalis L. and its ethyl acetate and n-butyl alcohol fractions have demonstrated significant antitussive and anti-inflammatory effects in preclinical studies. This area of investigation appears primarily within the context of traditional Chinese medicine research.

4.10 Atherosclerosis and Lipid Metabolism

Verbena officinalis, as a Chinese herbal medicine, exhibits anti-inflammatory, analgesic, immunomodulatory, and neuroprotective effects. Evidence suggests that it regulates lipid metabolism. An integrated network pharmacology approach, molecular docking, and molecular dynamics simulation identified 209 potential targets for the 11 main ingredients in V. officinalis, with 147 intersection targets between V. officinalis and atherosclerosis. Quercetin, luteolin, and kaempferol were considered key ingredients for the potential treatment of atherosclerosis. This is computational and theoretical evidence only; no clinical trials have been reported.

4.11 Purported Galactogogue (Lactation Support)

Vervain is a purported galactogogue; however, no scientifically valid clinical trials support this use. Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production.

5. Body Systems and Health Areas of Association

• Central nervous system: Anxiolytic, sedative, antidepressant, and anticonvulsant activity — demonstrated preclinically; no confirmed human data.
• Digestive system: Traditional use recognized by the EMA for relieving mild digestive complaints (sluggish digestion, bloating).
• Oral/Dental health: Anti-gingivitis effects supported by one multicenter RCT.
• Musculoskeletal and inflammatory: Anti-inflammatory and analgesic effects demonstrated in animal models, with traditional use for rheumatism and gout.
• Reproductive system: Historically used for dysmenorrhea and amenorrhea; analgesic and anti-inflammatory activity cited as mechanistic rationale in preclinical models.
• Neurological (neuroprotection): In vitro and animal evidence for protection against Alzheimer's-type neurodegeneration via verbascoside and aqueous extracts.
• Respiratory: Traditional use for cough, asthma, and bronchitis; antitussive effects documented preclinically; part of a combination product (Sinupret) with some clinical evidence for sinusitis.
• Hepatobiliary: Traditional use for jaundice and liver/gallbladder disease; hepatoprotective signals in preclinical research.
• Cardiovascular: Network pharmacology analyses suggest potential effects on lipid metabolism and atherosclerosis via constituent flavonoids, but this remains theoretical.

6. Dosage Forms and Reported Dosages

There is no clinical evidence to support specific dose recommendations for vervain. The following dosages are reported only as they appear in the reviewed sources:

• Dried herb infusion (traditional): Traditional use for its astringent properties required 2 to 4 g daily in an infusion.
• Tincture (traditional): If using a tincture, 5–10 ml can be taken three times a day, as reported in traditional dosage guidance.
• Antidepressant animal study dose: In the rat model, the aqueous extract (VAE) was administered orally at 200 mg/kg for 7 successive days.
• Sleep study animal doses: Hastatoside at 0.64 mmol/kg of body weight and verbenalin at 1.28 mmol/kg of body weight were used in the rat EEG sleep study.
• Anticonvulsant/sedative animal study: In the thiopental-induced sleeping test, the crude extract was administered at 50–300 mg/kg.

Vervain is "generally recognized as safe" (GRAS) as a food by the U.S. Food and Drug Administration.

7. Safety Considerations and Interactions

General Safety Profile

Vervain is "generally recognized as safe" (GRAS) as a food by the U.S. Food and Drug Administration. It is well tolerated, but gastrointestinal and allergic reactions have been reported. Formal contraindications have not been identified. Research reveals little or no information regarding adverse reactions with the use of this product.

Pregnancy and Lactation

Vervain is not recommended in pregnancy due to its emmenagogue actions. Verbenalin is considered toxic in high doses and is a potential abortifacient, so vervain should not be used by pregnant women. No data exist on the excretion of any components of vervain into breastmilk or on the safety and efficacy of vervain in nursing mothers or infants.

Allergic Contact Dermatitis

A case of allergic contact dermatitis from Verbena officinalis L. has been documented in the literature (Del Pozo et al., Contact Dermatitis, 1994). The combination product (Sinupret) can cause digestive system upset and occasionally allergic skin rash.

Drug Interactions

Vervain can interact with some high blood pressure and anticoagulant medications. These are potential, not well-characterized interactions; no formal pharmacokinetic interaction studies in humans have been identified in the reviewed sources.

Pre-Surgical Use

This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about herbal, vitamin, mineral, or any other supplements you are taking before any kind of surgery or medical procedure.

Overall Evidence Limitations

A large body of literature summarizes traditional medicinal uses and pharmacological in vitro and in vivo studies proving antioxidant, antimicrobial, anti-inflammatory, neuroprotective, anticancer, analgesic, and anticonvulsant applications of verbena herb extracts. However, the decisive limitation of the current evidence base is the near-complete absence of controlled human clinical trials. The gingivitis RCT (Grawish et al., 2016, n = 260) stands as the most rigorously designed human intervention study published for a single-herb V. officinalis preparation. All other pharmacological claims rest on preclinical (animal and cell-based) evidence. Standardization of extracts is also a recognized challenge: there is debate over standardizing extract quality, as variability in verbenalin content complicates dosing studies.

References

• Verbena officinalis L. Herb Extract, Its Amino Acid Preparations and 3D-Printed Dosage Forms — PMC (2025)
• Verbena Officinalis — ScienceDirect Topics Overview
• Investigation of Bioactive Compounds Extracted from Verbena officinalis — PMC (2025)
• Metabolic Profiling by GC-MS, In Vitro Biological Potential, and In Silico Molecular Docking Studies of Verbena officinalis — PMC (2022)
• Verbena officinalis (Common Vervain) — Planta Medica, Thieme Connect (2020)
• Short-term effects of Verbena officinalis Linn decoction on patients suffering from chronic generalized gingivitis: Double-blind randomized controlled multicenter clinical trial — PubMed (2016)
• Evaluating the Antidepressant Effect of Verbena officinalis L. (Vervain) Aqueous Extract in Adult Rats — PMC (2020)
• Anticonvulsant, Anxiolytic, and Sedative Activities of Verbena officinalis — Frontiers in Pharmacology, PMC (2016)
• Integrating transcriptome and chemical analyses to reveal the anti-Alzheimer's disease components in Verbena officinalis Linn — Frontiers in Plant Science, PMC (2022)
• Novel neuroprotective effects of the aqueous extracts from Verbena officinalis Linn — PubMed (2006)
• Neuroprotective effects of verbascoside against Alzheimer's disease via the relief of endoplasmic reticulum stress — PMC (2020)
• The Neuroprotection of Verbascoside in Alzheimer's Disease Mediated through Mitigation of Neuroinflammation via Blocking NF-κB-p65 Signaling — PMC (2022)
• Key ingredients in Verbena officinalis and determination of their anti-atherosclerotic effect using computer-aided drug design — PMC (2023)
• Activity and Stability Studies of Verbascoside, a Novel Antioxidant, in Dermo-Cosmetic and Pharmaceutical Topical Formulations — PMC (2018)
• Multifaceted Biological Properties of Verbascoside/Acteoside: Antimicrobial, Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects — Antibiotics, MDPI (2025)
• Vervain — Drugs and Lactation Database (LactMed), NCBI Bookshelf
• Vervain Uses, Benefits & Dosage — Drugs.com (2026)
• Verbena officinalis — Wikipedia
• Vervain (Verbena officinalis): Benefits, Uses, Safety — Herbal Reality
• Verbena (Verveine) Tea — Thés & Traditions (references EMA HMPC monograph on Verbena officinalis)